STAT3 and diffuse large B-cell lymphoma: Both treatments resulted in decreased expression levels of HLX in L-540 and EBV-positive DOHH-2 cells (Fig 3G), supporting that activated/phosphorylated and nuclear/deacetylated STAT3 activates HLX expression in DLBCL cell line DOHH-2 as well.